PanAdipo

1. PanAdipo is associated with hyperlipidemia in humans (Exploratory health system analyses; BMI-adjusted) (HR 1.11 (1.04–1.18); Hartung-Knapp intervals crossed 1).

   “and hyperlipidemia (1.11 [1.04-1.18]), with modest precision (Hartung-Knapp intervals crossed 1).”

   HumansExploratory health system analyses; BMI-adjusted

   Heart ultrasound model flags fat linked to metabolic risk

   Journal of the American College of Cardiology·Nov 1, 2026

More on Hyperlipidemia

1. PanAdipo is associated with steatotic liver disease in humans (Exploratory health system analyses; BMI-adjusted) (HR 1.33 (1.11–1.59) per SD of log[PanAdipo]; Hartung-Knapp intervals crossed 1).

   “higher scores were associated with newly documented steatotic liver disease (pooled BMI-adjusted HR 1.33 [1.11-1.59] per SD of log[PanAdipo])”

   HumansExploratory health system analyses; BMI-adjusted

   Heart ultrasound model flags fat linked to metabolic risk

   Journal of the American College of Cardiology·Nov 1, 2026

More on Steatotic liver disease

1. PanAdipo is associated with HOMA-IR in humans (MESA; adjusted for age, sex, and BMI) (β=0.17 per SD; 95% CI, 0.11–0.22).

   “In MESA, higher scores were associated with an adverse metabolic profile (higher HOMA-IR [β=0.17 per SD; 95% CI, 0.11-0.22; n=950])”

   HumansMESA; adjusted for age, sex, and BMIn = 950

   Heart ultrasound model flags fat linked to metabolic risk

   Journal of the American College of Cardiology·Nov 1, 2026

More on HOMA-IR

1. PanAdipo predicts CT-defined high indexed epicardial adipose tissue volume in silico (EAT/heart volume ≥95th percentile) (AUROC 0.90 (95% CI, 0.89–0.92)).

   “PanAdipo discriminated age- and sex-specific high EAT (EAT/heart volume ≥95th percentile) with an AUROC of 0.90 (95% CI, 0.89-0.92) overall”

   In silicoEAT/heart volume ≥95th percentileepicardial adipose tissuen = 5,167

   Heart ultrasound model flags fat linked to metabolic risk

   Journal of the American College of Cardiology·Nov 1, 2026

More on CT-defined high indexed epicardial adipose tissue volume

1. PanAdipo is linked with a higher risk of metabolic dysfunction-associated steatotic liver disease in humans (BMI-adjusted in TTE and POCUS cohorts) (HR 1.31 [1.03-1.67]).

   “higher scores were associated with newly documented MASLD/MASH (BMI-adjusted HRpooled 1.31 [1.03-1.67] per SD of log[PanAdipo])”

   HumansBMI-adjusted in TTE and POCUS cohorts

   AI-Enabled Echocardiography Identifies Prominent Epicardial Adipose Tissue Associated With an Adverse Cardiometabolic Profile

   medRxiv : the preprint server for health sciences·Aug 1, 2026Preprint

More on Metabolic dysfunction-associated steatotic liver disease

1. PanAdipo predicts epicardial adipose tissue volume in silico (against CT-derived measurements) (AUROCs of 0.91 to 0.95).

   “Against paired CT-derived measurements, PanAdipo discriminated age- and sex-specific high EAT (EAT/heart volume ≥95th percentile) with AUROCs of 0.91 to 0.95 across age-sex groups”

   In silicoagainst CT-derived measurementsheartn = 5,167

   AI-Enabled Echocardiography Identifies Prominent Epicardial Adipose Tissue Associated With an Adverse Cardiometabolic Profile

   medRxiv : the preprint server for health sciences·Aug 1, 2026Preprint

More on Epicardial adipose tissue volume